Clinical haemophilia Haemophilia care in Europe – a survey of 35 countries

A questionnaire was circulated in 2012 to national haemophilia patient organizations in Europe affiliated to the European Haemophilia Consortium (EHC) and the World Federation of Hemophilia (WFH) to seek information about the organization of haemophilia care and treatment available at a national level. The 35 responses received highlighted major differences in the availability of treatment and care. There was a wide range in factor VIII consumption with usage ranging from 0.20 IU per capita in Armenia to 8.56 IU per capita in Sweden (median: IU per capita). The decrease in health budgets in many countries was not matched by decreases in use of FVIII per capita. In the 19 countries that responded to the previous survey, there was a significant improvement in access to prophylaxis and home treatment.

[1]  A. Farrugia,et al.  Health technology assessment and haemophilia , 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

[2]  P. Giangrande,et al.  Haemophilia care in Europe: a survey of 19 countries , 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

[3]  J. Stonebraker,et al.  A study of reported factor VIII use around the world , 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

[4]  J. Astermark,et al.  European principles of haemophilia care , 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

[5]  P. Giangrande,et al.  Good dental care , 2005, British Dental Journal.